基本信息
浏览量:268
职业迁徙
个人简介
Alan P. Kozikowski was born in 1948 in Menominee, MI. He received his Ph.D. degree from the University of California, Berkeley, under the supervision of the late Professor W. G. Dauben. After postdoctoral work with Professor E. J. Corey at Harvard University, Dr. Kozikowski began his independent career at the University of Pittsburgh. After 14 years there, he spent 3 years at the Mayo Clinic and then moved on to the Georgetown University Medical Center, where he is the Director of the Drug Discovery Program. Dr. Kozikowski's interests are in the areas of drug abuse, medications development, second messenger based therapeutics for cancer, and novel chemical interventions for the treatment of Alzheimer's disease.
Dr. Kozikowski's group is a medicinal chemistry group that is involved in research at the interface of organic chemistry and biology. Specifically, the the group uses the latest methods of organic synthesis combined with information gleaned from the methods of molecular modeling (both small molecule and protein modeling) to design and synthesize molecules that can be used to gain a better understanding of the function of specific molecular targets. A host of new target macromolecules continue to be identified as a consequence of the power of molecular biology, combined with a better understanding of signal transduction pathways and gene transcription. The research has generated several novel pharmacological research tools which may serve as a steppingstone to the design of therapeutic agents. The modeling methods involve extensive computational experience, whereas the preparation of a specific target molecule in the lab utilizes techniques of organic chemistry coupled with modern methods of chemical analysis including FT-IR, high field NMR, GC-MS. Additionally, the chemistry group makes use of combinatorial chemistry methods and has one of the latest robotics systems for chemical library generation.
Dr. Kozikowski's group focuses on broad areas of neuroscience. The group was the first in the world to carry out the synthesis of the Alzheimer's agent huperzine A. In collaboration with researchers at WRAIR, this remarkable molecule has been shown to work as a potent of acetylcholinesterase and to possess neuroprotective properties through its action at NMDA receptors. Because of much of Dr. Kozikowski's efforts, this molecule is now currently marketed for use in the treatment of memory disorders. The group is also actively involved in the generation of novel transporter ligands, and in particular, in the identification of therapeutics for the treatment of cocaine abuse. Presently, the group has identified a transporter ligand that acts only partially like cocaine. This molecule has been studied in primates, and is being further advanced by NIDA's medications development program for use in humans. The group is also actively involved in the identification of new tools for furthering our understanding of a family of glutamate receptors know as the metabotropic glutamate family, in collaboration with Dr. Joe Neale and Jarda Wroblewski. Again, novel ligands have been found which have been shown to act in unique ways, and which possess neuroprotective properties. Lastly, the group has been active in the design of agents that act at the regulatory site of PKC. These efforts involve extensive molecular modeling of the target protein. As PKC is a ubiquitous signaling molecule, ligands capable of binding to it have potential use in Alzheimer's disease. Through the collaborative projects with neuroscientists at GUMC, ligands developed for binding to PKC have been found effective in the modulation of amyloid processing.
研究兴趣
论文共 837 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Transplantation (2024)
crossref(2023)
ACS CHEMICAL BIOLOGYno. 7 (2023): 1594-1610
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn